About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases.

News

March 14, 2019
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results

March 14, 2019
Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million

March 13, 2019
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time

Events

March 21, 2019
ARM’s Cell & Gene Therapy Investor Day

March 14, 2019
Caladrius Biosciences 4th Quarter 2018 Financial Results and Business Update Conference Call

February 12, 2019
Caladrius Biosciences to Present at the 2019 BIO CEO Investor Conference

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology